A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG‐ACRIN Cancer Research Group (E2607)
Kevin Kalinsky(Emory University), John M. Kirkwood(UPMC Hillman Cancer Center), Anthony J. Iafrarte(Massachusetts General Hospital), Andrew L. Pecora(Hackensack University Medical Center), Krista M. Rubin(Massachusetts General Hospital), Mario M. Leitão(Memorial Sloan Kettering Cancer Center), Henry Koon(Case Western Reserve University), Donald P. Lawrence(Massachusetts General Hospital), Anthony J. Jaslowski(Saint Vincent Hospital), Darell R. Borger(Massachusetts General Hospital), Gary I. Cohen(Greater Baltimore Medical Center), Timothy M. Kuzel(Rush University), Christopher D. Lao(University of Michigan), Ahmad A. Tarhini(UPMC Hillman Cancer Center)
Cited by 125
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
|Journal of the American College of Cardiology|2018|1.5k
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
|Nature Communications|2017|999